Dystrophic Epidermolysis Bullosa – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Dystrophic epidermolysis bullosa is one of the most common types of epidermolysis bullosa. The skin is expected to be highly fragile and to blister easily. Blisters and skin erosions result from minor injury or friction, such as scratching or rubbing. The Dystrophic epidermolysis bullosa signs and symptoms vary widely between individuals. In mild cases, blistering may primarily affect the hands, knees, feet, and elbows. Severe cases of this condition cause widespread blistering, which can result in vision loss, scarring, and other serious medical problems. Mutations cause DEB in the COL7A1 gene encoding type VII collagen. Type VII collagen is a major component of the anchoring fibril located below the basement membrane in the upper dermis, providing stable dermal-epidermal adhesion. Type VII collagen is a homotrimer composed of three proα1 (VII) chains which are encoded by the 32 kb COL7A1 gene on chromosome 3p21. DEB has two patterns of inheritance: autosomal dominant (DDEB) and autosomal recessive (RDEB). DEB has three common variants, namely, “DDEB, generalized”, “RDEB, generalized severe”, and “RDEB, generalized intermediate”, as well as other rare variants.

·       The incidence of Dystrophic epidermolysis bullosa varies between 2.5 to 6.8 cases per 1,000,000 live births.

Thelansis’s “Dystrophic Epidermolysis Bullosa Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dystrophic Epidermolysis Bullosa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Dystrophic Epidermolysis Bullosa across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Dystrophic Epidermolysis Bullosa Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Dystrophic Epidermolysis Bullosa – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032